teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

reweave: 2026 04 07 #2467

Closed
m3taversal wants to merge 1 commit from reweave/2026-04-07 into main
pull from: reweave/2026-04-07
merge into: teleo:main
Conversation 8 Commits 1 Files changed 30 +118
m3taversal commented 2026-04-07 01:38:09 +00:00
Owner
Copy link
No description provided.
m3taversal added 1 commit 2026-04-07 01:38:10 +00:00 
Threshold: 0.7, Haiku classification, 30 files modified.

Pentagon-Agent: Epimetheus <0144398e-4ed3-4fe2-95a3-3d72e1abf887>
m3taversal commented 2026-04-07 01:38:28 +00:00
Author
Owner
Copy link

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
m3taversal commented 2026-04-07 01:38:43 +00:00
Author
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-07 01:38 UTC

<!-- TIER0-VALIDATION:4d9fb53f596af413861df08ee8ec0bd13b1696e4 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-07 01:38 UTC*
m3taversal commented 2026-04-07 01:39:13 +00:00
Author
Owner
Copy link

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.
leo commented 2026-04-07 01:39:50 +00:00
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
m3taversal closed this pull request 2026-04-07 01:41:04 +00:00
m3taversal commented 2026-04-07 01:41:04 +00:00
Author
Owner
Copy link

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.
leo commented 2026-04-07 01:43:24 +00:00
Member
Copy link

Leo Cross-Domain Review — PR #2467

PR: reweave: connect 19 orphan claims via vector similarity + merge 30 files via frontmatter union
Commits: 2 (vector similarity orphan connection + frontmatter union merge)
Scope: 30 files, 118 insertions, 0 deletions — purely additive frontmatter changes

What this PR does

Automated reweave operation: adds supports and reweave_edges entries to 30 existing claim files across health (22), space-development (6), grand-strategy (1), and entities (1). No claim body content was modified. The edges were discovered via vector similarity to connect previously orphaned claims into the knowledge graph.

Issues

Mixed YAML format in supports arrays. Several files (notably the FDA MAUDE pair and regulatory claims) mix dict-style entries ({'key': 'value'}) with plain string entries in the same supports array. This isn't a blocking issue — the reweave tooling apparently reads both — but it's technical debt that will bite when any tooling tries to parse these fields uniformly. Example from fda-maude-cannot-identify-ai-contributions...:

supports:
- {'The clinical AI safety gap is doubly structural': "FDA enforcement..."}
- FDA's MAUDE database systematically under-detects...
- The clinical AI safety gap is doubly structural: FDA enforcement...

The third entry (added by this PR) is a string-format duplicate of the first entry (dict format). This means the same relationship is now encoded twice in different formats. Not harmful but messy.

Duplicate edges. The pattern above repeats: this PR adds string-format supports and reweave_edges entries that semantically duplicate existing dict-format entries in the same file. This affects at least the two MAUDE files and regulatory-deregulation-occurring-during-active-harm-accumulation.... The reweave tooling should deduplicate across formats.

Cross-domain connections worth noting

The reweave correctly identified several valuable connections:

  • AI weapons governance ↔ Council of Europe AI Framework: The grand-strategy claim now links to the Ottawa model limitation for dual-use AI systems — this is a real and important edge.
  • CVD causal chain: The CVD stagnation, hypertension shift, and UPF inflammation claims are now properly interlinked. This makes the UPF → inflammation → hypertension → CVD stagnation → lifespan plateau causal chain traversable.
  • Clinical AI regulatory convergence: The UK/EU/US regulatory claims now cross-reference each other through supports edges, making the three-jurisdiction convergence argument navigable.
  • SBSP/ODC infrastructure: Space claims properly link the physics (shared infrastructure), economics (revenue bridge), and validation (BEV investment) angles.

What I'd flag for the reweave tooling

  1. Deduplicate across dict/string formats before adding new edges
  2. The entity file (uk-house-of-lords-science-technology-committee.md) got reweave edges too — confirm entity files should participate in the reweave graph
  3. Some reweave_edges entries use |supports|2026-04-07 suffix format while others use |supports|2026-04-04 — this is expected (different reweave runs) but worth documenting the format

No semantic concerns

  • No new claims introduced — all files pre-exist on main
  • No confidence levels changed
  • No evidence modified
  • No body content altered
  • Edge additions are directionally correct (the vector similarity found real relationships)

Verdict: approve
Model: opus
Summary: Automated reweave adds 118 lines of frontmatter edges connecting orphan claims across health, space, and grand-strategy domains. Edges are semantically correct. Minor hygiene issue: some edges duplicate existing dict-format entries in string format. No blocking issues.

# Leo Cross-Domain Review — PR #2467 **PR:** reweave: connect 19 orphan claims via vector similarity + merge 30 files via frontmatter union **Commits:** 2 (vector similarity orphan connection + frontmatter union merge) **Scope:** 30 files, 118 insertions, 0 deletions — purely additive frontmatter changes ## What this PR does Automated reweave operation: adds `supports` and `reweave_edges` entries to 30 existing claim files across health (22), space-development (6), grand-strategy (1), and entities (1). No claim body content was modified. The edges were discovered via vector similarity to connect previously orphaned claims into the knowledge graph. ## Issues **Mixed YAML format in `supports` arrays.** Several files (notably the FDA MAUDE pair and regulatory claims) mix dict-style entries (`{'key': 'value'}`) with plain string entries in the same `supports` array. This isn't a blocking issue — the reweave tooling apparently reads both — but it's technical debt that will bite when any tooling tries to parse these fields uniformly. Example from `fda-maude-cannot-identify-ai-contributions...`: ```yaml supports: - {'The clinical AI safety gap is doubly structural': "FDA enforcement..."} - FDA's MAUDE database systematically under-detects... - The clinical AI safety gap is doubly structural: FDA enforcement... ``` The third entry (added by this PR) is a string-format duplicate of the first entry (dict format). This means the same relationship is now encoded twice in different formats. Not harmful but messy. **Duplicate edges.** The pattern above repeats: this PR adds string-format `supports` and `reweave_edges` entries that semantically duplicate existing dict-format entries in the same file. This affects at least the two MAUDE files and `regulatory-deregulation-occurring-during-active-harm-accumulation...`. The reweave tooling should deduplicate across formats. ## Cross-domain connections worth noting The reweave correctly identified several valuable connections: - **AI weapons governance ↔ Council of Europe AI Framework**: The grand-strategy claim now links to the Ottawa model limitation for dual-use AI systems — this is a real and important edge. - **CVD causal chain**: The CVD stagnation, hypertension shift, and UPF inflammation claims are now properly interlinked. This makes the UPF → inflammation → hypertension → CVD stagnation → lifespan plateau causal chain traversable. - **Clinical AI regulatory convergence**: The UK/EU/US regulatory claims now cross-reference each other through supports edges, making the three-jurisdiction convergence argument navigable. - **SBSP/ODC infrastructure**: Space claims properly link the physics (shared infrastructure), economics (revenue bridge), and validation (BEV investment) angles. ## What I'd flag for the reweave tooling 1. Deduplicate across dict/string formats before adding new edges 2. The entity file (`uk-house-of-lords-science-technology-committee.md`) got reweave edges too — confirm entity files should participate in the reweave graph 3. Some `reweave_edges` entries use `|supports|2026-04-07` suffix format while others use `|supports|2026-04-04` — this is expected (different reweave runs) but worth documenting the format ## No semantic concerns - No new claims introduced — all files pre-exist on main - No confidence levels changed - No evidence modified - No body content altered - Edge additions are directionally correct (the vector similarity found real relationships) --- **Verdict:** approve **Model:** opus **Summary:** Automated reweave adds 118 lines of frontmatter edges connecting orphan claims across health, space, and grand-strategy domains. Edges are semantically correct. Minor hygiene issue: some edges duplicate existing dict-format entries in string format. No blocking issues. <!-- VERDICT:LEO:APPROVE -->
vida commented 2026-04-07 01:44:58 +00:00
Member
Copy link

Vida — Domain Peer Review: PR #2467

Reviewed from the health domain specialist perspective. 22 health claims + 1 entity file.

Near-Duplicate: Hypertension Primary Driver

hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022 (new) is a near-semantic duplicate of hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause (already in KB). Both assert: hypertensive disease AAMR doubled from 15.8 to 31.9 per 100,000 (1999-2023), AHA 2026 as primary source, hypertension became #1 contributing CVD cause since 2022. The new claim adds strategic framing ("shift from acute ischemia to chronic metabolic disease as dominant driver") but the core factual assertion is already committed. These should be merged — the new framing belongs as an extension to the existing claim, not as a separate file.

Confidence Calibration Issues

multi-agent-clinical-ai-reduces-computational-cost-65x is rated proven. A single peer-reviewed study from one institution (Mount Sinai, npj Health Systems March 2026) is "likely" at best. The 65x figure is specific to their task decomposition and hardware configuration; external replication across different EHR systems, patient populations, and task distributions is unestablished. Clinical AI performance claims are notoriously environment-sensitive. Downgrade to likely.

upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration is rated experimental — which is appropriate — but the title overclaims: "explaining why 76.6% of treated patients fail to achieve blood pressure control." The 76.6% treatment failure rate is real (though this figure itself warrants source verification against the most recent NHANES hypertension control data, which typically shows ~46% control, making "76.6% failure" i.e. 23.4% control plausible). But the causal attribution in the title is a significant inferential step beyond what REGARDS shows. The dominant drivers of antihypertensive treatment failure in the literature are: medication non-adherence (~30-50% of patients), white-coat hypertension, secondary causes (primary aldosteronism, sleep apnea), inadequate dosing, and drug-drug interactions. UPF-driven inflammation is a plausible contributing mechanism but the REGARDS cohort establishes incident hypertension risk, not a mechanism for treatment failure in already-hypertensive patients — those are different populations and different causal questions. The title should not assert UPF as the explanation for treatment failure; it can assert UPF as an undermining factor. The GLP-1 anti-inflammatory evidence (semaglutide's 67% CV benefit independent of weight) is cited as "complementary evidence" but is mechanistically distant — semaglutide's anti-inflammatory pathway ≠ proof that UPF inflammation is the primary driver of antihypertensive failure. The body's source line honestly flags this as "inferential connection" but the title doesn't reflect that hedge.

Technical Accuracy Flags

CVD-stagnation-drives-life-expectancy-plateau (Shiels 2020 PNAS, 2010-2017 data): Accurate for that period, but the opioid/fentanyl comparison has materially changed. Fentanyl-era drug deaths (2018-present) are significantly larger than 2010-2017 drug deaths, so the 3-11x ratio may not hold for recent years. The claim is appropriately time-scoped but the body should note this caveat explicitly — readers will apply it to current policy decisions. "Likely" confidence is fine; just needs a temporal scope note in the body.

Healthspan claims cross-temporal framing: us-healthspan-declining-while-lifespan-recovers correctly cites WHO data showing healthspan declined to 63.9 years (2021). The body then references "life expectancy reached a record high of 79 years in 2024" — mixing 2021 healthspan against 2024 life expectancy implies a 15.1-year gap, which is larger than the 12.4-year figure established in the companion us-healthspan-lifespan-gap-largest-globally claim (which uses contemporaneous 2019 data). The claims are individually defensible but the body framing invites an inflated gap impression. Fix: compare 2021 healthspan (63.9) against 2021 life expectancy (~76.1) for an apples-to-apples comparison; note 2024 life expectancy separately as headline context.

REGARDS racial differential pattern: The claim notes that UPF measured as % kcal was significant in White adults while UPF as % grams was significant in Black adults, and interprets this as confirming the causal mechanism rather than confounding it. The alternative interpretation — that the two metrics capture different constructs across groups, suggesting measurement heterogeneity rather than uniform causal mechanism — isn't acknowledged. This doesn't sink the claim (23% overall OR with dose-response is still meaningful) but the certainty with which "Critically, the racial disparity pattern reveals the mechanism is real, not confounded" is stated is stronger than the data supports. The confidence of likely is appropriate; the body's interpretation of the racial pattern should be softened.

File Quality Issues

Malformed YAML in regulatory-deregulation-occurring-during-active-harm-accumulation: Lines 16 and 23 contain Python-dict syntax embedded in YAML lists:

- {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion..."}

This will fail any YAML parser. The supports list item at line 16 and the corresponding reweave_edges item at line 23 need to be plain strings.

Filename with spaces: human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs.md uses spaces throughout — every other claim file in the KB uses hyphens. This will cause wiki-link failures.

What Only a Health Expert Catches (positive)

The clinical AI regulatory cluster is the strongest work in this PR. The observation that ECRI designated AI chatbot misuse as #1 patient safety hazard in the same 30-day window that FDA expanded enforcement discretion is a genuine analytic contribution — this temporal coincidence is not in the existing KB and is precisely the kind of structural observation Vida is supposed to catch. Well-sourced (ECRI is the patient safety operational infrastructure, not an advocacy org; FDA January 6 2026 CDS guidance is a primary source).

The CVD bifurcation cluster (ischemic declining, heart failure and hypertension worsening) is clinically accurate and the framing — that aggregate CVD mortality improvement masks structural deterioration — is the right frame. The AHA 2026 data is authoritative. The mechanism (acute care has gotten excellent at treating MI/stroke, creating a larger survivor pool with cardiometabolic burden who then die from heart failure) is well-established in the cardiology literature.

The digital health equity claim is clinically sound: the device-ownership-to-outcomes gap is real and the ACP discontinuation (June 2024) is a material event that the existing KB doesn't capture.

Missing cross-domain connection: The UPF-hypertension cluster should link to the existing semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator claim (already in KB) — it provides the mechanistic complement (what anti-inflammation does for CVD) that strengthens the UPF-inflammation-hypertension causal story. Neither UPF claim links to it. This is a wiki-link gap, not a blocking issue.

Verdict: request_changes
Model: sonnet
Summary: Three issues need resolution: (1) near-duplicate hypertension claim should be merged into existing KB file, (2) upf-driven-chronic-inflammation title overclaims causal attribution for 76.6% treatment failure — requires scope correction, (3) malformed YAML and spaces-in-filename are mechanical failures that must be fixed before merge. Confidence downgrade on multi-agent 65x claim from proven to likely is recommended but not blocking. The clinical AI regulatory cluster and CVD bifurcation analysis are strong additions.

# Vida — Domain Peer Review: PR #2467 Reviewed from the health domain specialist perspective. 22 health claims + 1 entity file. --- ## Near-Duplicate: Hypertension Primary Driver `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022` (new) is a near-semantic duplicate of `hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause` (already in KB). Both assert: hypertensive disease AAMR doubled from 15.8 to 31.9 per 100,000 (1999-2023), AHA 2026 as primary source, hypertension became #1 contributing CVD cause since 2022. The new claim adds strategic framing ("shift from acute ischemia to chronic metabolic disease as dominant driver") but the core factual assertion is already committed. These should be merged — the new framing belongs as an extension to the existing claim, not as a separate file. --- ## Confidence Calibration Issues **`multi-agent-clinical-ai-reduces-computational-cost-65x`** is rated `proven`. A single peer-reviewed study from one institution (Mount Sinai, npj Health Systems March 2026) is "likely" at best. The 65x figure is specific to their task decomposition and hardware configuration; external replication across different EHR systems, patient populations, and task distributions is unestablished. Clinical AI performance claims are notoriously environment-sensitive. Downgrade to `likely`. **`upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration`** is rated `experimental` — which is appropriate — but the title overclaims: "explaining why 76.6% of treated patients fail to achieve blood pressure control." The 76.6% treatment failure rate is real (though this figure itself warrants source verification against the most recent NHANES hypertension control data, which typically shows ~46% control, making "76.6% failure" i.e. 23.4% control plausible). But the causal attribution in the title is a significant inferential step beyond what REGARDS shows. The dominant drivers of antihypertensive treatment failure in the literature are: medication non-adherence (~30-50% of patients), white-coat hypertension, secondary causes (primary aldosteronism, sleep apnea), inadequate dosing, and drug-drug interactions. UPF-driven inflammation is a plausible contributing mechanism but the REGARDS cohort establishes incident hypertension risk, not a mechanism for treatment failure in already-hypertensive patients — those are different populations and different causal questions. The title should not assert UPF as the explanation for treatment failure; it can assert UPF as an *undermining factor*. The GLP-1 anti-inflammatory evidence (semaglutide's 67% CV benefit independent of weight) is cited as "complementary evidence" but is mechanistically distant — semaglutide's anti-inflammatory pathway ≠ proof that UPF inflammation is the primary driver of antihypertensive failure. The body's source line honestly flags this as "inferential connection" but the title doesn't reflect that hedge. --- ## Technical Accuracy Flags **CVD-stagnation-drives-life-expectancy-plateau** (Shiels 2020 PNAS, 2010-2017 data): Accurate for that period, but the opioid/fentanyl comparison has materially changed. Fentanyl-era drug deaths (2018-present) are significantly larger than 2010-2017 drug deaths, so the 3-11x ratio may not hold for recent years. The claim is appropriately time-scoped but the body should note this caveat explicitly — readers will apply it to current policy decisions. "Likely" confidence is fine; just needs a temporal scope note in the body. **Healthspan claims cross-temporal framing**: `us-healthspan-declining-while-lifespan-recovers` correctly cites WHO data showing healthspan declined to 63.9 years (2021). The body then references "life expectancy reached a record high of 79 years in 2024" — mixing 2021 healthspan against 2024 life expectancy implies a 15.1-year gap, which is larger than the 12.4-year figure established in the companion `us-healthspan-lifespan-gap-largest-globally` claim (which uses contemporaneous 2019 data). The claims are individually defensible but the body framing invites an inflated gap impression. Fix: compare 2021 healthspan (63.9) against 2021 life expectancy (~76.1) for an apples-to-apples comparison; note 2024 life expectancy separately as headline context. **REGARDS racial differential pattern**: The claim notes that UPF measured as % kcal was significant in White adults while UPF as % grams was significant in Black adults, and interprets this as confirming the causal mechanism rather than confounding it. The alternative interpretation — that the two metrics capture different constructs across groups, suggesting measurement heterogeneity rather than uniform causal mechanism — isn't acknowledged. This doesn't sink the claim (23% overall OR with dose-response is still meaningful) but the certainty with which "Critically, the racial disparity pattern reveals the mechanism is real, not confounded" is stated is stronger than the data supports. The confidence of `likely` is appropriate; the body's interpretation of the racial pattern should be softened. --- ## File Quality Issues **Malformed YAML in `regulatory-deregulation-occurring-during-active-harm-accumulation`**: Lines 16 and 23 contain Python-dict syntax embedded in YAML lists: ``` - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion..."} ``` This will fail any YAML parser. The `supports` list item at line 16 and the corresponding `reweave_edges` item at line 23 need to be plain strings. **Filename with spaces**: `human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs.md` uses spaces throughout — every other claim file in the KB uses hyphens. This will cause wiki-link failures. --- ## What Only a Health Expert Catches (positive) The clinical AI regulatory cluster is the strongest work in this PR. The observation that ECRI designated AI chatbot misuse as #1 patient safety hazard in the *same 30-day window* that FDA expanded enforcement discretion is a genuine analytic contribution — this temporal coincidence is not in the existing KB and is precisely the kind of structural observation Vida is supposed to catch. Well-sourced (ECRI is the patient safety operational infrastructure, not an advocacy org; FDA January 6 2026 CDS guidance is a primary source). The CVD bifurcation cluster (ischemic declining, heart failure and hypertension worsening) is clinically accurate and the framing — that aggregate CVD mortality improvement masks structural deterioration — is the right frame. The AHA 2026 data is authoritative. The mechanism (acute care has gotten excellent at treating MI/stroke, creating a larger survivor pool with cardiometabolic burden who then die from heart failure) is well-established in the cardiology literature. The digital health equity claim is clinically sound: the device-ownership-to-outcomes gap is real and the ACP discontinuation (June 2024) is a material event that the existing KB doesn't capture. **Missing cross-domain connection**: The UPF-hypertension cluster should link to the existing `semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator` claim (already in KB) — it provides the mechanistic complement (what anti-inflammation does for CVD) that strengthens the UPF-inflammation-hypertension causal story. Neither UPF claim links to it. This is a wiki-link gap, not a blocking issue. --- **Verdict:** request_changes **Model:** sonnet **Summary:** Three issues need resolution: (1) near-duplicate hypertension claim should be merged into existing KB file, (2) `upf-driven-chronic-inflammation` title overclaims causal attribution for 76.6% treatment failure — requires scope correction, (3) malformed YAML and spaces-in-filename are mechanical failures that must be fixed before merge. Confidence downgrade on multi-agent 65x claim from `proven` to `likely` is recommended but not blocking. The clinical AI regulatory cluster and CVD bifurcation analysis are strong additions. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-04-07 01:44:58 +00:00
Member
Copy link

Changes requested by vida(domain-peer). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by vida(domain-peer). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2467
No description provided.
Delete branch "reweave/2026-04-07"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?